These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 31272264)

  • 1. Efficacy and safety of the switch of Triumeq
    Pérez-Stachowski J; Tortajada B; Del Arco A; Márquez E; De la Torre J; Nieto M; García de Lomas JM; Prada JL; García-Alegría J; Olalla J
    Infect Dis (Lond); 2019 Sep; 51(9):691-693. PubMed ID: 31272264
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of the switch of Triumeq® to generic (abacavir + lamivudine) + Tivicay®: data at 24 weeks.
    Olalla J; Pérez-Stachowski J; Tortajada B; Del Arco A; Márquez E; De la Torre J; Nieto M; García de Lomas JM; Prada JL; García-Alegría J
    BMC Pharmacol Toxicol; 2018 Oct; 19(1):63. PubMed ID: 30305176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness, Safety, and Costs of Dolutegravir/Abacavir/Lamivudine Single-Tablet Regimen in a Real-Life Cohort of HIV-1 Adult Infected Patients.
    Rodriguez-Gonzalez CG; Chamorro-de-Vega E; Ortega-Navarro C; Alonso R; Herranz-Alonso A; Sanjurjo-Saez M
    Ann Pharmacother; 2020 Jul; 54(7):633-643. PubMed ID: 31910643
    [No Abstract]   [Full Text] [Related]  

  • 4. Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study.
    Trottier B; Lake JE; Logue K; Brinson C; Santiago L; Brennan C; Koteff JA; Wynne B; Hopking J; Granier C; Aboud M
    Antivir Ther; 2017; 22(4):295-305. PubMed ID: 28401876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. De-simplifying single-tablet antiretroviral treatments: uptake, risks and cost savings.
    Krentz HB; Campbell S; Lahl M; Gill MJ
    HIV Med; 2019 Mar; 20(3):214-221. PubMed ID: 30632660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-utility analysis of the fixed-dose combination of dolutegravir/abacavir/lamivudine as initial treatment of HIV+ patients in Spain.
    Moreno Guillen S; Losa García JE; Berenguer Berenguer J; Martínez Sesmero JM; Cenoz Gomis S; Graefenhain R; Lopez Sanchez-Cambronero D; Parrondo Garcia FJ
    Farm Hosp; 2017 Sep; 41(5):601-610. PubMed ID: 28847249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and tolerability of dolutegravir and abacavir/lamivudine administered as two separate pills compared to their equivalent single-tablet regimen in a multicentre cohort in Spain.
    Suárez-García I; Alejos B; Ruiz-Algueró M; García Yubero C; Moreno C; Bernal E; Pérez-Is L; Zubero Z; de Zárraga Fernández MA; Samperiz Abad G; Jarrín I;
    J Int AIDS Soc; 2021 Jul; 24(7):e25758. PubMed ID: 34291580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient perspectives on de-simplifying their single-tablet co-formulated antiretroviral therapy for societal cost savings.
    Krentz HB; Campbell S; Gill VC; Gill MJ
    HIV Med; 2018 Apr; 19(4):290-298. PubMed ID: 29368401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A retrospective clinical audit of general practices in Australia to determine the motivation for switch to dolutegravir/abacavir/lamivudine and clinical outcomes.
    Ferrer PE; Bloch M; Roth N; Finlayson R; Baker D; Koh K; Orth D; Urbaityte R; Brown D; Drummond F
    Int J STD AIDS; 2018 Mar; 29(3):300-305. PubMed ID: 28901212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dolutegravir Monotherapy Versus Dolutegravir/Abacavir/Lamivudine for Virologically Suppressed People Living With Chronic Human Immunodeficiency Virus Infection: The Randomized Noninferiority MONotherapy of TiviCAY Trial.
    Hocqueloux L; Raffi F; Prazuck T; Bernard L; Sunder S; Esnault JL; Rey D; Le Moal G; Roncato-Saberan M; André M; Billaud E; Valéry A; Avettand-Fènoël V; Parienti JJ; Allavena C;
    Clin Infect Dis; 2019 Oct; 69(9):1498-1505. PubMed ID: 30601976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness of Dolutegravir as a First-Line Treatment Option in the HIV-1-Infected Treatment-Naive Patients in Russia.
    Tremblay G; Chounta V; Piercy J; Holbrook T; Garib SA; Bukin EK; Punekar YS
    Value Health Reg Issues; 2018 Sep; 16():74-80. PubMed ID: 30296624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abacavir/lamivudine/dolutegravir single tablet regimen in patients with human immunodeficiency virus and end-stage renal disease on hemodialysis.
    Michienzi SM; Schriever CA; Badowski ME
    Int J STD AIDS; 2019 Feb; 30(2):181-187. PubMed ID: 30381029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.
    Walmsley SL; Antela A; Clumeck N; Duiculescu D; Eberhard A; Gutiérrez F; Hocqueloux L; Maggiolo F; Sandkovsky U; Granier C; Pappa K; Wynne B; Min S; Nichols G;
    N Engl J Med; 2013 Nov; 369(19):1807-18. PubMed ID: 24195548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abacavir/dolutegravir/lamivudine single-tablet regimen: a review of its use in HIV-1 infection.
    Greig SL; Deeks ED
    Drugs; 2015 Apr; 75(5):503-14. PubMed ID: 25698454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
    Molina JM; Ward D; Brar I; Mills A; Stellbrink HJ; López-Cortés L; Ruane P; Podzamczer D; Brinson C; Custodio J; Liu H; Andreatta K; Martin H; Cheng A; Quirk E
    Lancet HIV; 2018 Jul; 5(7):e357-e365. PubMed ID: 29925489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dolutegravir, abacavir and lamivudine as HIV therapy.
    Fernandez-Montero JV; Barreiro P; Labarga P; De Mendoza C; Soriano V
    Expert Opin Pharmacother; 2014 May; 15(7):1051-7. PubMed ID: 24754315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States.
    Girouard MP; Sax PE; Parker RA; Taiwo B; Freedberg KA; Gulick RM; Weinstein MC; Paltiel AD; Walensky RP
    Clin Infect Dis; 2016 Mar; 62(6):784-91. PubMed ID: 26658053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of switching to abacavir/lamivudine (ABC/3TC) plus rilpivirine (RPV) in virologically suppressed HIV-infected patients on HAART.
    Palacios R; Pérez-Hernández IA; Martínez MA; Mayorga ML; González-Domenech CM; Omar M; Olalla J; Romero A; Romero JM; Pérez-Camacho I; Hernández-Quero J; Santos J
    Eur J Clin Microbiol Infect Dis; 2016 May; 35(5):815-9. PubMed ID: 26879392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir.
    Wohl DA; Bhatti L; Small CB; Edelstein H; Zhao HH; Margolis DA; DeJesus E; Weinberg WG; Ross LL; Shaefer MS
    HIV Med; 2016 Feb; 17(2):106-17. PubMed ID: 26176344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DOLAMA study: Effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients.
    Hidalgo-Tenorio C; Cortés LL; Gutiérrez A; Santos J; Omar M; Gálvez C; Sequera S; Jesús SE; Téllez F; Fernández E; García C; Pasquau J
    Medicine (Baltimore); 2019 Aug; 98(32):e16813. PubMed ID: 31393412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.